NCT05550337View on ClinicalTrials.gov

Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream) In The Treatment Of Acne Vulgaris

PHASE3CompletedINTERVENTIONAL
Enrollment

807

Participants

Timeline

Start Date

September 19, 2022

Primary Completion Date

May 9, 2023

Study Completion Date

May 9, 2023

Conditions
Acne Vulgaris
Interventions
DRUG

Trifarotene 0.005 % Topical Cream

Cream

DRUG

AKLIEF®

Cream

DRUG

Placebo

Cream

Trial Locations (14)

15241

Site 10010, Saint Clair

33027

Site 10005, Miramar

33175

Site 10004, Miami

33308

Site 10003, Fort Lauderdale

33511

Site 10001, Brandon

33609

Site 10002, Tampa

70115

Site 10011, New Orleans

70809

Site 10012, Baton Rouge

Site 10013, Baton Rouge

75234

Site 10009, Dallas

79902

Site 10006, El Paso

79925

Site 10007, El Paso

88011

Site 10008, Las Cruces

91790

Site 10011, West Covina

All Listed Sponsors
collaborator

Teva Pharmaceuticals, Inc.

INDUSTRY

lead

Teva Pharmaceuticals USA

INDUSTRY